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Background
Clinical studies with multiple CGRP receptor antagonists
reported that CGRP receptor antagonism is effective in
acute migraine reversal. Using XenoMouse® Technology,
we successfully generated a group of human monoclonal
antibodies (mAb) that specifically target the human CGRP
receptor.
Aim
to characterize the pharmacological properties of AMG
334, one of the mAbs currently in clinical development for
migraine prevention
Methods
We used [125I]-CGRP and [125I]-AMG 334 binding
assays to measure AMG 334/CGRP-receptor interactions,
cell-based cAMP assays to study functional activity and
selectivity of AMG 334, and a laser Doppler model in
cynomolgus (cyno) macaque to assess the pharmacody-
namic effects of blocking capsaicin-induced increases in
dermal blood flow with AMG 334.
Results
AMG 334 is a potent inhibitor of [125I]-CGRP binding to
the human CGRP receptor with a Ki of 0.02 nM. It exhib-
ited full inhibition of CGRP-stimulated cAMP production
with an IC50 of 2.3 nM in cell-based functional assays.
Potency of AMG 334 at the cyno CGRP receptor is similar
to that at the human receptor, but with significant reduced
potency at dog, rabbit and rat receptors. AMG 334 also
demonstrates > 5000-fold selectivity over other closely
related receptors in the family. The receptor kinetics
studies using [125I]-AMG 334 reveals a dissociation t1/2
off of 67 min.
In the cyno study, AMG 334 produces a significant
and sustained inhibitory effect on capsaicin-induced
increase in dermal blood flow.
Conclusion
AMG 334 is a potent and selective antibody against the
human CGRP receptor with potential for migraine
prevention.
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